Florence I. Raynaud

19.2k citations

242 papers · 10.2k indexed · 2 hit papers · h-index 55

Molecular Biology top 1%
Oncology top 1%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 1%
Organic Chemistry top 2%

Co-authors: Paul Workman Ian Judson Paul A. Clarke Johann S. de Bono Lloyd R. Kèlland Timothy A. Yap Michelle D. Garrett Finbarr E. Cotter
Topics: Microtubule and mitosis dynamics (23 papers)Cancer, Hypoxia, and Metabolism (22 papers)Cancer-related Molecular Pathways (20 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Proceedings of the National Academy of Sciences The Lancet Journal of Biological Chemistry
Partner nations: United Kingdom France United States

In The Last Decade

Florence I. Raynaud

238 papers receiving 10.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →
Effect of sleep deprivation on the human metabolome

2014 387 citations Joo Ern Ang, Victoria L. Revell et al. profile →

Peers

Countries citing papers authored by Florence I. Raynaud

Since Specialization

Citations

This map shows the geographic impact of Florence I. Raynaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence I. Raynaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence I. Raynaud more than expected).

Fields of papers citing papers by Florence I. Raynaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence I. Raynaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence I. Raynaud. The network helps show where Florence I. Raynaud may publish in the future.

Co-authorship network of co-authors of Florence I. Raynaud

This figure shows the co-authorship network connecting the top 25 collaborators of Florence I. Raynaud. A scholar is included among the top collaborators of Florence I. Raynaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence I. Raynaud. Florence I. Raynaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors 2020 ·Clinical Cancer Research ·(unknown),Rajiv Kumar,Dionysis Papadatos-Pastos,Joaquı́n Mateo,Jessica Brown,Alvaro Ingles Garces,Ruth Ruddle,Shaun Decordova,Simone Jueliger,Roberta Ferraldeschi,Óscar Maiques,Victoria Sanz‐Moreno,Paul S. Jones,Stephanie Traub,Gavin Halbert,(unknown),Karen E. Swales,Florence I. Raynaud,Michelle D. Garrett,Udai Banerji	52
2	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers 2019 ·Molecular Cancer Therapeutics ·Adam Stewart,Elizabeth A. Coker,Sebastian Pölsterl,(unknown),Anna Minchom,Suzanne Carreira,David Cunningham,Mary O’Brien,Florence I. Raynaud,Johann S. de Bono,Bissan Al‐Lazikani,Udai Banerji	14
3	De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy 2019 ·Autophagy ·Gabriela Andrejeva,Sharon Gowan,Gigin Lin,(unknown),(unknown),Harold G. Parkes,(unknown),Florence I. Raynaud,Yasmin J. Asad,Gema Vizcay‐Barrena,Joanna Nikitorowicz-Buniak,Melanie Valenti,Louise Howell,Roland A. Fleck,Lesley‐Ann Martin,Vladimir Kirkin,Martin O. Leach,Yuen‐Li Chung	76
4	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma 2017 ·Molecular Cancer Therapeutics ·Joo Ern Ang,Ákos Pál,Yasmin J. Asad,Alan T. Henley,Melanie Valenti,Gary Box,Alexis de Haven Brandon,Victoria L. Revell,Debra J. Skene,Miro Venturi,Ruediger Rueger,Valérie Méresse,Suzanne A. Eccles,Johann S. de Bono,Stanley B. Kaye,Paul Workman,Udai Banerji,Florence I. Raynaud	8
5	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance 2016 ·Cancer Research ·Orli Yogev,Karen Barker,(unknown),Gilberto S. Almeida,Albert Hallsworth,Laura Smith,Yann Jamin,Ruth Ruddle,Alexander Koers,Hannah Webber,Florence I. Raynaud,Sergey Popov,Chris Jones,Kevin Petrie,Simon P. Robinson,Hector C. Keun,Louis Chesler	32
6	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation 2016 ·Molecular Cancer Therapeutics ·Joo Ern Ang,(unknown),(unknown),Yasmin J. Asad,Alan T. Henley,Melanie Valenti,Gary Box,Alexis de Haven Brandon,Richard D. Baird,Lori S. Friedman,Mika K. Derynck,Bart Vanhaesebroeck,Suzanne A. Eccles,Stan B. Kaye,Paul Workman,Johann S. de Bono,Florence I. Raynaud	16
7	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo 2013 ·Clinical Cancer Research ·Jane Renshaw,Kathryn R. Taylor,Ryan T. Bishop,Melanie Valenti,Alexis de Haven Brandon,Sharon Gowan,Suzanne A. Eccles,Ruth Ruddle,Louise D. Johnson,Florence I. Raynaud,Joanna Selfe,Khin Thway,Torsten Pietsch,Andrew D.J. Pearson,Janet Shipley	110
8	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs 2012 ·Clinical Cancer Research ·Mike I. Walton,Paul D. Eve,Angela Hayes,Melanie Valenti,Alexis K. de Haven Brandon,Gary Box,Albert Hallsworth,(unknown),Kathy Boxall,Michael Lainchbury,Thomas P. Matthews,Yann Jamin,Simon P. Robinson,G. Wynne Aherne,John Reader,Louis Chesler,Florence I. Raynaud,Suzanne A. Eccles,Ian Collins,Michelle D. Garrett	69
9	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors 2012 ·Clinical Cancer Research ·Udai Banerji,Leni van Doorn,Dionysis Papadatos-Pastos,Rebecca Kristeleit,Phillip Debnam,(unknown),Adam Stewart,Florence I. Raynaud,Michelle D. Garrett,Martin Toal,Leon Hooftman,Johann S. de Bono,Jaap Verweij,Ferry A.L.M. Eskens	64
10	Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β 2011 ·Molecular Cancer Therapeutics ·Aleksandra Bielen,Lara Perryman,Gary Box,Melanie Valenti,Alexis de Haven Brandon,Vanessa Martins,Alexa Jury,Sergey Popov,Sharon Gowan,Sébastien Jeay,Florence I. Raynaud,Francesco Hofmann,Darren Hargrave,Suzanne A. Eccles,Chris Jones	41
11	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Simon Pacey,Richard H. Wilson,Mike Walton,Martin Eatock,Anthea Hardcastle,(unknown),Hendrik‐Tobias Arkenau,(unknown),Udai Banerji,Belle Roels,(unknown),Wynne Aherne,Johann S. de Bono,Florence I. Raynaud,Paul Workman,Ian Judson	154
12	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In Vivo 2011 ·Molecular Cancer Therapeutics ·Amir Faisal,(unknown),Vassilios Bavetsias,Chongbo Sun,Butrus Atrash,(unknown),Yann Jamin,Simon P. Robinson,Paul Workman,Julian Blagg,Florence I. Raynaud,Suzanne A. Eccles,Louis Chesler,Spiros Linardopoulos	67
13	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription 2010 ·Cancer Research ·Kenneth Ewan,Bożena Pająk,Mark Stubbs,(unknown),Olivier Barbeau,Camilo Quevedo,Hannah Botfield,Rodrigo Young,Ruth Ruddle,(unknown),Alysia Battersby,Florence I. Raynaud,Nicholas D. Allen,Stephen W. Wilson,Branko Latinkic,Paul Workman,Edward McDonald,Julian Blagg,Wynne Aherne,Trevor Dale	86
14	Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic 2010 ·Cancer Research ·Paul Workman,Paul A. Clarke,Florence I. Raynaud,Rob L. M. van Montfort	211
15	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 2010 ·Molecular Cancer Therapeutics ·Timothy A. Yap,Mike I. Walton,(unknown),Melanie Valenti,Alexis de Haven Brandon,Paul D. Eve,Ruth Ruddle,Simon P. Heaton,Alan T. Henley,Lisa Pickard,Gowri Vijayaraghavan,John Caldwell,Neil T. Thompson,Wynne Aherne,Florence I. Raynaud,Suzanne A. Eccles,Paul Workman,Ian Collins,Michelle D. Garrett	59
16	The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy 2010 ·Cancer Research ·Nada M.S. Al-Saffar,L. Elizabeth Jackson,Florence I. Raynaud,Paul A. Clarke,Ana Ramı́rez de Molina,Juan Carlos Lacal,Paul Workman,Martin O. Leach	54
17	The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 2010 ·Molecular Cancer Therapeutics ·Michael I. Walton,Paul D. Eve,Angela Hayes,Melanie Valenti,Alexis de Haven Brandon,Gary Box,Kathy Boxall,G. Wynne Aherne,Suzanne A. Eccles,Florence I. Raynaud,D. H. Williams,John Reader,Ian Collins,Michelle D. Garrett	63
18	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Drivenbreakdown → 2008 ·Journal of Clinical Oncology ·Gerhardt Attard,Alison Reid,Timothy A. Yap,Florence I. Raynaud,Mitch Dowsett,S. Settatree,Mary Barrett,Christopher Parker,Vanessa Martins,Elizabeth Folkerd,J. W. Clark,Colin S. Cooper,Stan B. Kaye,David P. Dearnaley,Gloria Lee,Johann S. de Bono	666
19	Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models 2005 ·Clinical Cancer Research ·Udai Banerji,Michael I. Walton,Florence I. Raynaud,Rachel Grimshaw,Lloyd R. Kèlland,(unknown),Ian Judson,Paul Workman	126
20	BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors 2005 ·Cancer Research ·David D. Gibbs,Davinder S. Theti,(unknown),Matthew Green,Florence I. Raynaud,Melanie Valenti,Martin Förster,(unknown),Vassilios Bavetsias,(unknown),Ann L. Jackman	86

About Florence I. Raynaud

Florence I. Raynaud is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 242 papers that have together received 10.2k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (23 papers), Cancer, Hypoxia, and Metabolism (22 papers) and Cancer-related Molecular Pathways (20 papers). The work is most often cited by research in Oncology (2.6k citations), Cancer Research (1.2k citations) and Molecular Biology (5.5k citations). Florence I. Raynaud has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Paul Workman, Ian Judson, Paul A. Clarke, Johann S. de Bono, Lloyd R. Kèlland, Timothy A. Yap, Michelle D. Garrett, Finbarr E. Cotter, David Cunningham and Melanie Valenti. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact